First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study (Q49790677)
Jump to navigation
Jump to search
scientific article published on 15 December 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study |
scientific article published on 15 December 2017 |
Statements
1 reference
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study (English)
1 reference
Keith Flaherty
1 reference
Mario Sznol
1 reference
Filip Janku
1 reference
Antoni Ribas
1 reference
Elizabeth Buchbinder
1 reference
Jeffrey R Infante
1 reference
Jeffrey A Sosman
1 reference
Ryan J Sullivan
1 reference
Deborah Jean Lee Wong
1 reference
Vicki Keedy
1 reference
Manish R Patel
1 reference
Geoffrey I Shapiro
1 reference
James W Mier
1 reference
Anthony W Tolcher
1 reference
Andrea Wang-Gillam
1 reference
Richard D Carvajal
1 reference
Anna M Varghese
1 reference
Mario E Lacouture
1 reference
Sapna P Patel
1 reference
Gary A DeCrescenzo
1 reference
Caroline M Emery
1 reference
Anna L Groover
1 reference
Saurabh Saha
1 reference
Mary Varterasian
1 reference
Dean J Welsch
1 reference
David M Hyman
1 reference
Bob T Li
1 reference
15 December 2017
1 reference
1 reference
1 reference